H
Hernan Valdez
Researcher at Pfizer
Publications - 89
Citations - 4350
Hernan Valdez is an academic researcher from Pfizer. The author has contributed to research in topics: Tofacitinib & Janus kinase inhibitor. The author has an hindex of 31, co-authored 89 publications receiving 3297 citations. Previous affiliations of Hernan Valdez include Harvard University & University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Hervé Bachelez,Peter C.M. van de Kerkhof,Robert Strohal,Alexey Kubanov,Fernando Valenzuela,Joo-Heung Lee,Vladimir Yakusevich,Sergio Chimenti,Jocelyne Papacharalambous,J. Proulx,Pankaj Gupta,Huaming Tan,Margaret Tawadrous,Hernan Valdez,Robert Wolk +14 more
TL;DR: This phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-week, non-inferiority trial aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population of chronic stable plaque psoriasis.
Journal ArticleDOI
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop,Hisashi Yamanaka,Hernan Valdez,Eric Mortensen,Robert Chew,Sriram Krishnaswami,Thomas T. Kawabata,R. Riese +7 more
TL;DR: The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.
Journal ArticleDOI
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Eric L. Simpson,Rodney Sinclair,Seth Forman,Andreas Wollenberg,Roland Aschoff,Michael J. Cork,Thomas Bieber,Jacob P. Thyssen,Gil Yosipovitch,Carsten Flohr,Nina Magnolo,Catherine Maari,Claire Feeney,Pinaki Biswas,Svitlana Tatulych,Hernan Valdez,Ricardo Rojo +16 more
TL;DR: Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis and the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocITinib 100 mg group than in the placebo group.
Journal ArticleDOI
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Jonathan I. Silverberg,Eric L. Simpson,Jacob P. Thyssen,Melinda Gooderham,Gary Chan,Claire Feeney,Pinaki Biswas,Hernan Valdez,Marco DiBonaventura,Chudy I. Nduaka,Ricardo Rojo +10 more
TL;DR: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD) and laboratory values indicating thrombocytopenia.
Journal ArticleDOI
Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic.
Dong Zhang,Premlata Shankar,Premlata Shankar,Zhan Xu,Zhan Xu,Brooke Harnisch,Brooke Harnisch,Gang Chen,Gang Chen,Christoph Lange,Christoph Lange,Sandra J. Lee,Sandra J. Lee,Hernan Valdez,Hernan Valdez,Michael M. Lederman,Michael M. Lederman,Judy Lieberman,Judy Lieberman +18 more
TL;DR: The results suggest that the chance to eradicate an infection by T-cell-mediated lysis may be undermined once an infection becomes chronic, and impaired antiviral cytotoxicity during chronic infection likely represents the immune response to chronic antigenic exposure.